Bhatia Shivank, Bhatia Ansh, Richardson Andrew J, Richardson Kenneth, Issa Chloe, Kumar Jessica G, Jalaiean Hamed, Kava Bruce, Shah Hemendra N
Department of Interventional Radiology, University of Miami, Miller School of Medicine, Miami, Florida.
Department of Interventional Radiology, University of Miami, Miller School of Medicine, Miami, Florida.
J Vasc Interv Radiol. 2025 Mar;36(3):456-466. doi: 10.1016/j.jvir.2024.11.002. Epub 2024 Nov 10.
To assess the mid- to long-term safety and effectiveness of prostatic artery embolization (PAE) at a single-center cohort of 1,075 patients.
This institutional review board-approved retrospective study included patients with moderate-to-severe lower urinary tract symptoms (LUTS) or urinary retention who underwent PAE from January 2014 to July 2023. Patients were assessed at 1, 3, 6, and 12 months after PAE and yearly thereafter. The International Prostate Symptom Score (IPSS), quality of life (QoL) score, International Index of Erectile Function-5 (IIEF-5) score, prostate-specific antigen (PSA), prostate volume (PV), postvoid residual, benign prostatic obstruction (BPO) medication usage, urinary catheter status, and further prostatic interventions were assessed. Adverse events were recorded and classified using the Society of Interventional Radiology (SIR) adverse events (AEs) severity classification.
The mean follow-up was 458.4 days (SD ± 559.5). The mean age was 70.4 years (SD ± 9.0), the median (interquartile range) PV was 107 g (76-150 g), and the median preprocedural IPSS, QoL, and IIEF-5 scores and PSA level were 23 (18-28), 5 (4-6), 17 (10-21), and 4.7 ng/mL (2.6-8), respectively. In the LUTS subgroup, at 1-3, 6-12, and 48-60 months, the median IPSS values were 7 (4-12, P < .001), 6 (3-11, P < .001), and 9 (4-15, P < .001), respectively. The QoL scores at the same time points were 2 (1-2, P < .001), 1 (0-2, P < .001), 2 (0-3, P < .001), respectively. Of 126 patients in the retention cohort, 119 (94%) were catheter-free at the 3-month follow-up. Ninety-patients (16% of reintervention eligible patients) required a second prostatic intervention up to 60 months after PAE. After PAE, 65.5% of patients were BPO medication-free at 1 year. Seven patients (0.65%) had severe AEs according to the SIR AE severity classification: (a) transient ischemic attacks, 3; (b) urosepsis, 2 (treated in the inpatient setting with intravenous antibiotics); and (c) prostate sloughing, 2 (needing transurethral resection of the prostate). All AEs resolved without permanent sequelae.
In a large cohort with long-term longitudinal follow-up, PAE showed significant, sustained long-term relief of LUTS, improved QoL, low reintervention rate, and high BPO medication-free rates. Ninety-four percent of catheter-dependent patients at baseline were catheter-free at 3 months.
评估在一个包含1075例患者的单中心队列中,前列腺动脉栓塞术(PAE)的中长期安全性和有效性。
这项经机构审查委员会批准的回顾性研究纳入了2014年1月至2023年7月期间接受PAE治疗的中重度下尿路症状(LUTS)或尿潴留患者。在PAE术后1、3、6和12个月以及此后每年对患者进行评估。评估国际前列腺症状评分(IPSS)、生活质量(QoL)评分、国际勃起功能指数-5(IIEF-5)评分、前列腺特异性抗原(PSA)、前列腺体积(PV)、残余尿量、良性前列腺梗阻(BPO)药物使用情况、导尿管状态以及进一步的前列腺干预措施。使用介入放射学会(SIR)不良事件(AE)严重程度分类记录并分类不良事件。
平均随访时间为458.4天(标准差±559.5)。平均年龄为70.4岁(标准差±9.0),PV的中位数(四分位间距)为107 g(76 - 150 g),术前IPSS、QoL和IIEF-5评分以及PSA水平的中位数分别为23(18 - 28)、5(4 - 6)、17(10 - 21)和4.7 ng/mL(2.6 - 8)。在LUTS亚组中,在1 - 3个月、6 - 12个月和48 - 60个月时,IPSS的中位数分别为7(4 - 12,P <.001)、6(3 - 11,P <.001)和9(4 - 15,P <.001)。同时点的QoL评分分别为2(1 - 2,P <.001)、1(0 - 2,P <.001)、2(0 - 3,P <.001)。在尿潴留队列的126例患者中,94%(119例)在3个月随访时无需导尿管。90例患者(占符合再次干预条件患者的16%)在PAE术后60个月内需要进行第二次前列腺干预。PAE术后1年,65.5%的患者无需使用BPO药物。根据SIR AE严重程度分类,7例患者(0.65%)发生严重AE:(a)短暂性脑缺血发作,3例;(b)尿脓毒症,2例(在住院环境中接受静脉抗生素治疗);(c)前列腺脱落,2例(需要经尿道前列腺切除术)。所有AE均缓解,无永久性后遗症。
在一个进行长期纵向随访的大型队列中,PAE显示出LUTS得到显著、持续的长期缓解,QoL改善,再次干预率低,且无需使用BPO药物的比例高。基线时依赖导尿管的患者中,94%在3个月时无需导尿管。